FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer

X Fu, R Jeselsohn, R Pereira… - Proceedings of the …, 2016 - National Acad Sciences
X Fu, R Jeselsohn, R Pereira, EF Hollingsworth, CJ Creighton, F Li, M Shea, A Nardone…
Proceedings of the National Academy of Sciences, 2016National Acad Sciences
Forkhead box protein A1 (FOXA1) is a pioneer factor of estrogen receptor α (ER)–chromatin
binding and function, yet its aberration in endocrine-resistant (Endo-R) breast cancer is
unknown. Here, we report preclinical evidence for a role of FOXA1 in Endo-R breast cancer
as well as evidence for its clinical significance. FOXA1 is gene-amplified and/or
overexpressed in Endo-R derivatives of several breast cancer cell line models. Induced
FOXA1 triggers oncogenic gene signatures and proteomic profiles highly associated with …
Forkhead box protein A1 (FOXA1) is a pioneer factor of estrogen receptor α (ER)–chromatin binding and function, yet its aberration in endocrine-resistant (Endo-R) breast cancer is unknown. Here, we report preclinical evidence for a role of FOXA1 in Endo-R breast cancer as well as evidence for its clinical significance. FOXA1 is gene-amplified and/or overexpressed in Endo-R derivatives of several breast cancer cell line models. Induced FOXA1 triggers oncogenic gene signatures and proteomic profiles highly associated with endocrine resistance. Integrated omics data reveal IL8 as one of the most perturbed genes regulated by FOXA1 and ER transcriptional reprogramming in Endo-R cells. IL-8 knockdown inhibits tamoxifen-resistant cell growth and invasion and partially attenuates the effect of overexpressed FOXA1. Our study highlights a role of FOXA1 via IL-8 signaling as a potential therapeutic target in FOXA1-overexpressing ER-positive tumors.
National Acad Sciences